Esperion Therapeutics, Inc.

ESPRSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1434868

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$116.3M	$75.5M	$75.5M	$78.4M	$148.4M
Selling, General and Administrative Expense	$142.5M	$109.1M	$109.1M	$185.0M	$65.9M
Operating Expenses	$271.9M	$255.0M	$255.0M	$305.2M	$241.5M
Operating Income (Loss)	-$155.6M	-$179.5M	-$179.5M	-$226.7M	-$93.1M
Interest Expense	—	—	$56.8M	$46.4M	$8.1M
Other Nonoperating Income (Expense)	$5.3M	$2.7M	$2.7M	$4.0M	$4.1M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$209.2M	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$343.8M	$205.8M	$247.9M	$381.6M	$353.3M
Assets, Current	$338.0M	$201.1M	$246.7M	$329.0M	$345.9M
Cash and Cash Equivalents, at Carrying Value	$144.8M	$82.2M	$124.8M	$208.9M	$305.0M
Accounts Receivable, after Allowance for Credit Loss, Current	$80.1M	$48.5M	$33.7M	$22.9M	$12.4M
Inventory, Net	$94.5M	$65.6M	$35.2M	$34.4M	$16.1M
Liabilities	$732.5M	$660.8M	$571.7M	$578.5M	$449.4M
Liabilities, Current	$246.2M	$156.2M	$92.3M	$73.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$135.5M	-$174.8M	-$174.8M	-$263.8M	-$70.3M
Net Cash Provided by (Used in) Investing Activities	$42.5M	$8.1M	$8.1M	-$50.5M	$64.2M
Net Cash Provided by (Used in) Financing Activities	$50.5M	$32.6M	$32.6M	$268.2M	$136.2M
Payments to Acquire Property, Plant, and Equipment	$0.00	$0.00	—	—	$953.0K
Payments for Repurchase of Common Stock	$55.0M	$55.0M	$55.0M	$55.0M	$0.00

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)